MET overexpression are observed at a frequency of 0% in the precursors of nonatypical form, 67% in atypical form, 92% in the relatively differentiated carcinoma components and 100% in the poorly differentiated carcinoma components, supporting the notion that MET is one of the key drivers of carcinogenesis 86. The gene discussed is MET; the disease is carcinoma.